文献产品
| 结构式 | 货号 | 产品名称 | CAS号 |
|---|
 |
BCP21111 | 普托马尼 新 | 187235-37-6 |
PA-824 is an experimental anti-tuberculosis drug and one of two nitroimidazoles in phase II clinical trials to treat tuberculosis.
|
|||
 |
BCP02173 | Galunisertib 新 促 | 700874-72-2 |
LY2157299 is a novel selective small molecule transforming growth factor beta receptor (TGF-βR) kinase inhibitor with IC50 of 86 nM and 2 nM for TβR1 and 2 nM, respectively.
|
|||
 |
BCP07472 | 孕二烯二酮 新 | 39025-23-5 |
Z-guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. Z-guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis.
|
|||
 |
BCP03777 | 利巴韦林 新 | 36791-04-5 |
Ribavirin is a nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
|
|||
 |
BCP20310 | 英夫利昔单抗 新 | 170277-31-3 |
Infliximab is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
|
|||
 |
BCP02893 | 贝尔纳卡桑 新 热 | 273404-37-8 |
Belnacasan (VX-765) is an orally absorbed prodrug of VRT-043198, which exhibits potent inhibition against ICE/caspase-1 and caspase-4 with Ki of 0.8 nM and less than 0.6 nM, respectively.
|
|||
 |
BCP16068 | BMS-202 新 | 1675203-84-5 |
BMS-202 is an inhibitor of the PD-1/PD-L1 protein/protein interaction, mainly used for cancer treatment.
|
|||
 |
BCP14589 | 替格瑞洛杂质G 新 | 220347-05-7 |
Deshydroxyethoxy Ticagrelor analog of Ticagrelor an antiplatelet agent, and preventative in the treatment of heart attacks, myocardial infarction, and other pulmonary diseases.
|
|||
 |
BCP15784 | Fexaramine 新 | 574013-66-4 |
Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity relative to natural compounds.
|
|||
 |
BCP02037 | 泊那替尼 新 | 943319-70-8 |
Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN.
|
|||
 |
BCP01827 | Luminespib 新 | 747412-49-3 |
Luminespib is a potent HSP90 inhibitor with IC50s of 7.8 and 21 nM for HSP90α and HSP90β, respectively.
|
|||
 |
BCP02391 | Ostarine 新 大货 | 841205-47-8 |
Ostarine (MK-2866) is an androgen receptor modulator (SARM) with an ED50 of 0.44 mg/day.
|
|||
 |
BCP28287 | CB-839 | 1439399-58-2 |
CB-839 is a potent and orally bioavailable inhibitor of both splice variants of glutaminase (KGA and GAC), and with IC50s of 23 nM and 28 nM in kidney and brain, respectively.
|
|||
 |
BCP01841 | Mirdametinib 新 | 391210-10-9 |
Mirdametinib, also known as PD-0325901, is a potent bioavailable and selective MEK inhibitor, which targets mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity.
|
|||
 |
BCP01714 | GDC-0941 新 | 957054-30-7 |
Pictilisib, also known as Pictrelisib, GDC-0941, RG7321 and GNE0941 , is an orally bioavailable, and is a potent small-molecule thieno[3,2-d]pyrimidine inhibitor of the class I phosphatidylinositol 3 kinase (PI3K) isoforms p100alpha and p100delta with potential antineoplastic activity.
|
|||
 |
BCP01984 | Orantinib 新 | 252916-29-3 |
TSU-68 (SU6668)is a novel multiple receptor tyrosine kinase inhibitor with IC50 of 2.1 μM, 8 nM and 1.2 μM for VEGF-R1, PDGF-Rβ and FGF-R1, respectively.
|
|||
 |
BCP01874 | 拉帕替尼 新 | 231277-92-2 |
Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
|
|||
 |
BCP02857 | 喜树碱 新 | 7689-03-4 |
Camptothecin is a potent DNA enzyme topoisomerase I inhibitor with an IC50 and IC70 of 50 nM and 0.225 μM for breast cancer cell line MDA-MB-231.
|
|||
 |
BCP00195 | LY294002 新 | 154447-36-6 |
LY294002 is a highly selective inhibitor of phosphatidylinositol 3-kinase.
|
|||
 |
BCP01404 | 雷帕霉素 新 | 53123-88-9 |
Rapamycin is antifungal and immunosuppressant and specific inhibitor of mTOR.
|
|||
